- Home
- RBB vs TNGX Comparison
RBB vs TNGX Comparison
Compare RBB & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBB
- TNGX
- Stock Information
- Founded
- RBB 2008
- TNGX 2014
- Country
- RBB United States
- TNGX United States
- Employees
- RBB N/A
- TNGX N/A
- Industry
- RBB Major Banks
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- RBB Finance
- TNGX Health Care
- Exchange
- RBB Nasdaq
- TNGX Nasdaq
- Market Cap
- RBB 308.3M
- TNGX 317.4M
- IPO Year
- RBB 2017
- TNGX N/A
- Fundamental
- Price
- RBB $16.50
- TNGX $1.37
- Analyst Decision
- RBB Hold
- TNGX Strong Buy
- Analyst Count
- RBB 4
- TNGX 7
- Target Price
- RBB $21.25
- TNGX $12.33
- AVG Volume (30 Days)
- RBB 33.2K
- TNGX 789.1K
- Earning Date
- RBB 04-21-2025
- TNGX 05-07-2025
- Dividend Yield
- RBB 3.89%
- TNGX N/A
- EPS Growth
- RBB N/A
- TNGX N/A
- EPS
- RBB 1.47
- TNGX N/A
- Revenue
- RBB $104,842,000.00
- TNGX $42,069,000.00
- Revenue This Year
- RBB $15.69
- TNGX N/A
- Revenue Next Year
- RBB $7.66
- TNGX N/A
- P/E Ratio
- RBB $11.18
- TNGX N/A
- Revenue Growth
- RBB N/A
- TNGX 15.17
- 52 Week Low
- RBB $16.27
- TNGX $1.33
- 52 Week High
- RBB $25.30
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- RBB 37.06
- TNGX 26.22
- Support Level
- RBB $16.27
- TNGX $1.48
- Resistance Level
- RBB $17.49
- TNGX $1.66
- Average True Range (ATR)
- RBB 0.58
- TNGX 0.16
- MACD
- RBB 0.03
- TNGX -0.01
- Stochastic Oscillator
- RBB 16.08
- TNGX 5.63
About RBB RBB Bancorp
RBB Bancorp operates as a bank holding company. It provides various banking products and services such as checking, savings, money market accounts, and certificates of deposits. Its Specific services include remote deposit, E-banking, mobile banking, commercial and investor real estate loans, business loans and lines of credit, Small Business Administration (SBA) 7A and 504 loans, mortgage loans, trade finance, and a full range of depository accounts. It generates its revenue from interest received on loans and leases and, to a lesser extent, from interest received on investment securities and derives income from noninterest sources, such as fees received in connection with various lending and deposit services, loan servicing, gain on sales of loans, and wealth management services.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.